Roivant announces positive Phase 2 PHocus mosliciguat results
Roivant says it has positive results from its Phase 2 PHocus trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also unveils an ongoing Phase 3 PHrontier study.